Actemra (tocilizumab) (Intravenous)

Size: px
Start display at page:

Download "Actemra (tocilizumab) (Intravenous)"

Transcription

1 Actemra (tcilizumab) (Intravenus) Last Review Date: 06/01/2018 Date f Origin: 09/21/2010 Dcument Number: MODA-0002 Dates Reviewed: 12/2010, 03/2011, 05/2011, 06/2011, 09/2011, 12/2011, 03/2012, 06/2012, 09/2012, 09/2012, 11/2012, 12/2012, 03/2013, 06/2013, 09/2013, 11/2013, 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015, 5/2015, 9/2015, 12/0215, 03/2016, 06/2016, 09/2016, 12/2016, 03/2017, 05/2017, 09/2017, 12/2017, 03/2018, 06/2018 I. Length f Authrizatin Cverage will be prvided as fllws: Castleman s Disease: 4 mnths and may be renewed Cytkine Release Syndrme: 4 dses nly and may nt be renewed Immune Checkpint Inhibitr related arthritis: 1 dse and may nt be renewed All ther indicatins: 6 mnths and may be renewed. II. Dsing Limits A. Quantity Limit (max daily dse) [Pharmacy Benefit]: Actemra 80 mg/4 ml vial: 1 vial per 14 days Actemra 200 mg/10 ml vial: 1 vial per 14 days Actemra 400 mg/20 ml vial: 2 vials per 14 days B. Max Units (per dse and ver time) [Medical Benefit]: Diagnsis Billable Units Interval (days) Rheumatid Arthritis & Plyarticular Juvenile Idipathic Arthritis Systemic Juvenile Idipathic Arthritis & Castleman s Disease (NHL) Cytkine Release Syndrme (CRS) curse f therapy nly Immune Checkpint Inhibitr related arthritis curse f therapy nly III. Initial Apprval Criteria Site f care specialty infusin prgram requirements are met (refer t Mda Site f Care Plicy). Self-administered injectable medicatins are nt cvered when supplied in a prvider s ffice, clinic r facility. Cverage is prvided in the fllwing cnditins: Mda Health Plan, Inc. Medical Necessity Criteria Page 1/18

2 Patient has been evaluated and screened fr the presence f latent TB infectin prir t initiating treatment; AND Patient des nt have an active infectin, including clinically imprtant lcalized infectins; AND Must nt be administered cncurrently with live vaccines; AND Patient is nt n cncurrent treatment with anther TNF-inhibitr, bilgic respnse mdifier r ther nn-bilgic agent (i.e., apremilast); AND Rheumatid Arthritis Patient is 18 years r lder; AND Physician has assessed baseline disease severity utilizing an bjective measure/tl; AND Dcumented mderate t severe active disease; AND Patient has had at least a 3 mnth trial and failed previus therapy with ONE ral disease mdifying anti-rheumatic agent (DMARD) such as methtrexate, azathiprine, auranfin, hydrxychlrquine, penicillamine, sulfasalazine, leflunmide ; AND May be used alne r in cmbinatin with methtrexate; AND Patient must try and have an inadequate respnse, cntraindicatin, r intlerance t at least a three (3) mnth trial f Enbrel AND Humira; OR Patient is cntinuing treatment Juvenile Idipathic Arthritis (JIA) Patient is 2 years r lder ; AND Patient has active systemic (SJIA) r plyarticular (PJIA) disease; AND Physician has assessed baseline disease severity utilizing an bjective measure/tl; AND Patient has had at least a 1-mnth trial and failure (unless cntraindicated r intlerant) f previus therapy with either ral nn-steridal anti-inflammatry drugs (NSAIDs) OR a systemic gluccrticid (prednisne, methylprednislne, etc.); AND May be used alne r in cmbinatin with methtrexate; AND (Nte: The fllwing applies t plyarticular (PJIA) disease nly) Patient must try and have an inadequate respnse, cntraindicatin, r intlerance t at least a three (3) mnth trial f Enbrel AND Humira; OR Patient is cntinuing treatment Castleman s Disease (NHL) Used as a single agent; AND Patient has unicentric disease; AND Patient is human immundeficiency virus (HIV)-negative and human herpesvirus-8 (HHV-8)-negative; AND Used as secnd-line therapy fr relapsed r refractry disease; OR Patient has multicentric disease; AND Mda Health Plan, Inc. Medical Necessity Criteria Page 2/18

3 Used as subsequent therapy fr relapsed, refractry, r prgressive disease Cytkine Release Syndrme (CRS) Patient is 2 years r lder; AND Patient has received r will be receiving chimeric antigen receptr (CAR) T cell therapy; AND Tcilizumab is being rdered t have n-hand, prir t the administratin f CAR-T therapy, if needed fr the treatment f CRS; OR Patient has a cnfirmed diagnsis f CAR-T therapy induced severe r life-threatening CRS Management f Immune Checkpint Inhibitr related Inflammatry Arthritis Patient has been receiving therapy with an immune checkpint inhibitr (e.g. nivlumab, pembrlizumab, atezlizumab, avelumab, durvalumab, etc.); AND Patient has inflammatry arthritis related t their immuntherapy; AND Dcumented severe disease; AND Patient s cnditin is refractry t crticsterids and anti-inflammatry agents FDA Apprved Indicatin(s); Cmpendia Recmmended Indicatin(s) IV. Renewal Criteria Cverage can be renewed based upn the fllwing criteria: Patient cntinues t meet criteria identified in sectin III; AND Absence f unacceptable txicity frm the drug. Examples f unacceptable txicity include the fllwing: neutrpenia (abslute neutrphil cunt (ANC) belw 1000 per mm 3 ), thrmbcytpenia (platelet cunt belw 100,000 per mm 3 ), hepattxicity (ALT r AST abve 3-5 times the upper limit f nrmal), gastrintestinal perfratin, severe hypersensitivity reactins, etc.; AND Patient is receiving nging mnitring fr presence f TB r ther active infectins; AND (Onclgy Indicatins) Castleman s Disease (NHL) Tumr respnse with stabilizatin f disease r decrease in size f tumr r tumr spread (Nn-Onclgy Indicatins) Rheumatid arthritis (RA) Disease respnse as indicated by imprvement in signs and symptms cmpared t baseline such as the number f tender and swllen jint cunts and/r an imprvement n a disease activity scring tl [e.g. an imprvement n a cmpsite scring index such as Disease Activity Scre-28 (DAS28) f 1.2 pints r mre r a 20% imprvement n the American Cllege f Rheumatlgy-20 (ACR20) criteria] Juvenile Idipathic Arthritis (SJIA/PJIA) Disease respnse as indicated by imprvement in signs and symptms cmpared t baseline such as the number f tender and swllen jint cunts and/r an imprvement n a disease Mda Health Plan, Inc. Medical Necessity Criteria Page 3/18

4 activity scring tl [e.g. an imprvement n a cmpsite scring index such as Juvenile Arthritis Disease Activity Scre (JADAS) r the American Cllege f Rheumatlgy (ACR) Pediatric (ACR-Pedi 30) f at least 30% imprvement frm baseline in three f six variables]. Cytkine Release Syndrme May nt be renewed Management f Immune Checkpint Inhibitr related Inflammatry Arthritis May nt be renewed V. Dsage/Administratin Dses exceeding 800 mg per infusin are nt recmmended Indicatin Adult Rheumatid Arthritis Plyarticular Juvenile Idipathic Arthritis Systemic Juvenile Idipathic Arthritis Castleman s Disease (NHL) Cytkine Release Syndrme (CRS) Immune- Checkpint Inhibitr related inflammatry arthritis 4 mg/kg IV every 4 weeks Dse May increase t 8 mg/kg every 4 weeks based n clinical respnse Weight 30 kg 8 mg/kg IV every 4 weeks Weight < 30 kg 10 mg/kg IV every 4 weeks Weight 30 kg 8 mg/kg IV every 2 weeks Weight < 30 kg 12 mg/kg IV every 2 weeks 8 mg/kg IV every 2 weeks fr 16 weeks (8 dses) Weight 30 kg 8 mg/kg IV every 8 hurs, if needed, up t a maximum f 4 ttal dses* Weight < 30 kg 12 mg/kg IV every 8 hurs, if needed, up t a maximum f 4 ttal dses* *If n clinical imprvement in the signs and symptms f CRS ccurs after the first dse, up t 3 additinal dses may be administered. The interval between cnsecutive dses shuld be at least 8 hurs. May be used with r withut crticsterids. 4 mg/kg IV nce VI. Billing Cde/Availability Infrmatin Jcde: J3262 Injectin, tcilizumab, 1 mg; 1 billable unit = 1 mg NDC: Actemra 80 mg/ 4 ml vial: xx Mda Health Plan, Inc. Medical Necessity Criteria Page 4/18

5 Actemra 200 mg/10 ml vial: xx Actemra 400 mg/20 ml vial: xx VII. References 1. Actemra [package insert]. Suth San Francisc, CA; Genentech, Inc; March Accessed May Referenced with permissin frm the NCCN Drugs & Bilgics Cmpendium (NCCN Cmpendium ) tcilizumab. Natinal Cmprehensive Cancer Netwrk, The NCCN Cmpendium is a derivative wrk f the NCCN Guidelines. NATIONAL COMPREHENSIVE CANCER NETWORK, NCCN, and NCCN GUIDELINES are trademarks wned by the Natinal Cmprehensive Cancer Netwrk, Inc. T view the mst recent and cmplete versin f the Cmpendium, g nline t NCCN.rg. Accessed May Singh JA, Saag KG, Bridges SL Jr, et al American Cllege f Rheumatlgy Guideline fr the Treatment f Rheumatid Arthritis. Arthritis Care Res (Hbken) Nv 6. di: /acr Beukelman T, Patkar NM, Saag KG, et al American Cllege f Rheumatlgy recmmendatins fr the treatment f juvenile idipathic arthritis: initiatin and safety mnitring f therapeutic agents fr the treatment f arthritis and systemic features. Arthritis Care Res (Hbken) Apr;63(4): Ringld S, Weiss PF, Beukelman T, et al update f the 2011 American Cllege f Rheumatlgy recmmendatins fr the treatment f juvenile idipathic arthritis: recmmendatins fr the medical therapy f children with systemic juvenile idipathic arthritis and tuberculsis screening amng children receiving bilgic medicatins. Arthritis Rheum Oct;65(10): DeWitt EM, Kimura Y, Beukelman T, et al. Cnsensus treatment plans fr new-nset systemic juvenile idipathic arthritis. Arthritis Care Res (Hbken) Jul;64(7): Nishimt N, Kanakura Y, Azasa K, et al. Humanized anti-interleukin-6 receptr antibdy treatment f multicentric Castleman disease. Bld 2005;106: Smlen JS, Landewé R, Bijlsma J, et al. EULAR recmmendatins fr the management f rheumatid arthritis with synthetic and bilgical disease-mdifying antirheumatic drugs: 2016 update. Ann Rheum Dis Mar 6. pii: annrheumdis Fraser JA, Weyand CM, Newman NJ, Biusse V. The treatment f giant cell arteritis. Rev Neurl Dis Summer;5(3): Dasgupta B, Brg FA, Hassan N, et al. BSR and BHPR guidelines fr the management f giant cell arteritis. Rheumatlgy (Oxfrd) Aug;49(8): Natinal Institute fr Health and Care Excellence. NICE Rheumatid Arthritis in Adults: Management. Published 25 February Clinical Guideline [CG79] Natinal Institute fr Health and Care Excellence. NICE Adalimumab, etanercept, infliximab, rituximab and abatacept fr the treatment f rheumatid arthritis after failure f a TNF inhibitr. Published 10 Octber Clinical Guideline [TA195]. Mda Health Plan, Inc. Medical Necessity Criteria Page 5/18

6 tnf-inhibitr-pdf Ward MM, Guthri LC, Alba MI. Rheumatid Arthritis Respnse Criteria And Patient- Reprted Imprvement in Arthritis Activity: Is an ACR20 Respnse Meaningful t Patients. Arthritis Rheumatl Sep; 66(9): di: /art Ringld S, Bittner R, Neggi T, et al. Perfrmance f rheumatid arthritis disease activity measures and juvenile arthritis disease activity scres in plyarticular-curse juvenile idipathic arthritis: Analysis f their ability t classify the American Cllege f Rheumatlgy pediatric measures f respnse and the preliminary criteria fr flare and inactive disease. Arthritis Care Res (Hbken) Aug;62(8): Cnslar A, Giancane G, Schiappapietra B, et al. Clinical utcme measures in juvenile idipathic arthritis. Pediatric Rheumatlgy 18 April : Strud C, Hedge A, Cherry C, et al. Tciluzumab fr the management f immune mediated adverse events secndary t PD-1 blckage. Jurnal f Onclgy Pharmacy Practice December. Appendix 1 Cvered Diagnsis Cdes ICD-10 C82.00 Fllicular lymphma grade I, unspecified site C82.01 Fllicular lymphma grade I, lymph ndes f head, face and neck C82.02 Fllicular lymphma, grade I, intrathracic lymph ndes C82.03 Fllicular lymphma grade I, intra-abdminal lymph ndes C82.04 Fllicular lymphma grade I, lymph ndes f axilla and upper limb C82.05 Fllicular lymphma grade I, lymph ndes f inguinal reginal and lwer limb C82.06 Fllicular lymphma grade I, intrapelvic lymph ndes C82.07 Fllicular lymphma grade I, spleen C82.08 Fllicular lymphma grade I, lymph ndes f multiple sites C82.09 Fllicular lymphma grade I, extrandal and slid rgan sites C82.10 Fllicular lymphma grade II, unspecified site C82.11 Fllicular lymphma grade II, lymph ndes f head, face and neck C82.12 Fllicular lymphma, grade II, intrathracic lymph ndes C82.13 Fllicular lymphma grade II, intra-abdminal lymph ndes C82.14 Fllicular lymphma grade II, lymph ndes f axilla and upper limb C82.15 Fllicular lymphma grade II, lymph ndes f inguinal regin and lwer limb C82.16 Fllicular lymphma grade II, intrapelvic lymph ndes C82.17 Fllicular lymphma grade II, spleen C82.18 Fllicular lymphma grade II, lymph ndes f multiple sites C82.19 Fllicular lymphma grade II, extrandal and slid rgan sites C82.20 Fllicular lymphma grade III, unspecified, unspecified site C82.21 Fllicular lymphma grade III, unspecified, lymph ndes f head, face and neck Mda Health Plan, Inc. Medical Necessity Criteria Page 6/18

7 C82.22 Fllicular lymphma, grade III, unspecified, intrathracic lymph ndes C82.23 Fllicular lymphma grade III, unspecified, intra-abdminal lymph ndes C82.24 Fllicular lymphma grade III, unspecified, lymph ndes f axilla and upper limb C82.25 Fllicular lymphma grade III, unspecified, lymph ndes f inguinal regin and lwer limb C82.26 Fllicular lymphma grade III, unspecified, intrapelvic lymph ndes C82.27 Fllicular lymphma grade III, unspecified, spleen C82.28 Fllicular lymphma grade III, unspecified, lymph ndes f multiple sites C82.29 Fllicular lymphma grade III, unspecified, extrandal and slid rgan sites C82.30 Fllicular lymphma grade IIIa, unspecified site C82.31 Fllicular lymphma grade IIIa, lymph ndes f head, face and neck C82.32 Fllicular lymphma, grade IIIa, intrathracic lymph ndes C82.33 Fllicular lymphma grade IIIa, intra-abdminal lymph ndes C82.34 Fllicular lymphma grade IIIa, lymph ndes f axilla and upper limb C82.35 Fllicular lymphma grade IIIa, lymph ndes f inguinal regin and lwer limb C82.36 Fllicular lymphma grade IIIa, intrapelvic lymph ndes C82.37 Fllicular lymphma grade IIIa, spleen C82.38 Fllicular lymphma grade IIIa, lymph ndes f multiple sites C82.39 Fllicular lymphma grade IIIa, extrandal and slid rgan sites C82.40 Fllicular lymphma grade IIIb, unspecified site C82.41 Fllicular lymphma grade IIIb, lymph ndes f head, face and neck C82.42 Fllicular lymphma, grade IIIb, intrathracic lymph ndes C82.43 Fllicular lymphma grade IIIb, intra-abdminal lymph ndes C82.44 Fllicular lymphma grade IIIb, lymph ndes f axilla and upper limb C82.45 Fllicular lymphma grade IIIb, lymph ndes f inguinal regin and lwer limb C82.46 Fllicular lymphma grade IIIb, intrapelvic lymph ndes C82.47 Fllicular lymphma grade IIIb, spleen C82.48 Fllicular lymphma grade IIIb, lymph ndes f multiple sites C82.49 Fllicular lymphma grade IIIb, extrandal and slid rgan sites C82.50 Diffuse fllicle center lymphma, unspecified site C82.51 Diffuse fllicle center lymphma, lymph ndes f head, face and neck C82.52 Diffuse fllicle center lymphma, intrathracic lymph ndes C82.53 Diffuse fllicle center lymphma, intra-abdminal lymph ndes C82.54 Diffuse fllicle center lymphma, lymph ndes f axilla and upper limb C82.55 Diffuse fllicle center lymphma, lymph ndes f inguinal regin and lwer limb C82.56 Diffuse fllicle center lymphma, intrapelvic lymph ndes C82.57 Diffuse fllicle center lymphma, spleen C82.58 Diffuse fllicle center lymphma, lymph ndes f multiple sites C82.59 Diffuse fllicle center lymphma, extrandal and slid rgan sites C82.60 Cutaneus fllicle center lymphma, unspecified site C82.61 Cutaneus fllicle center lymphma, lymph ndes f head, face and neck Mda Health Plan, Inc. Medical Necessity Criteria Page 7/18

8 C82.62 Cutaneus fllicle center lymphma, intrathracic lymph ndes C82.63 Cutaneus fllicle center lymphma, intra-abdminal lymph ndes C82.64 Cutaneus fllicle center lymphma, lymph ndes f axilla and upper limb C82.65 Cutaneus fllicle center lymphma, lymph ndes f inguinal regin and lwer limb C82.66 Cutaneus fllicle center lymphma, intrapelvic lymph ndes C82.67 Cutaneus fllicle center lymphma, spleen C82.68 Cutaneus fllicle center lymphma, lymph ndes f multiple sites C82.69 Cutaneus fllicle center lymphma, extrandal and slid rgan sites C82.80 Other types f fllicular lymphma, unspecified site C82.81 Other types f fllicular lymphma, lymph ndes f head, face and neck C82.82 Other types f fllicular lymphma, intrathracic lymph ndes C82.83 Other types f fllicular lymphma, intra-abdminal lymph ndes C82.84 Other types f fllicular lymphma, lymph ndes f axilla and upper limb C82.85 Other types f fllicular lymphma, lymph ndes f inguinal regin and lwer limb C82.86 Other types f fllicular lymphma, intrapelvic lymph ndes C82.87 Other types f fllicular lymphma, spleen C82.88 Other types f fllicular lymphma, lymph ndes f multiple sites C82.89 Other types f fllicular lymphma, extrandal and slid rgan sites C82.90 Fllicular lymphma, unspecified, unspecified site C82.91 Fllicular lymphma, unspecified, lymph ndes f head, face and neck C82.92 Fllicular lymphma, unspecified, intrathracic lymph ndes C82.93 Fllicular lymphma, unspecified, intra-abdminal lymph ndes C82.94 Fllicular lymphma, unspecified, lymph ndes f axilla and upper limb C82.95 Fllicular lymphma, unspecified lymph ndes f inguinal regin and lwer limb C82.96 Fllicular lymphma, unspecified, intrapelvic lymph ndes C82.97 Fllicular lymphma, unspecified, spleen C82.98 Fllicular lymphma, unspecified, lymph ndes f multiple sites C82.99 Fllicular lymphma, unspecified, extrandal and slid rgan sites C83.00 Small cell B-cell lymphma, unspecified site C83.01 Small cell B-cell lymphma, lymph ndes f head, face and neck C83.02 Small cell B-cell lymphma, intrathracic lymph ndes C83.03 Small cell B-cell lymphma, intra-abdminal lymph ndes C83.04 Small cell B-cell lymphma, lymph ndes f axilla and upper limb C83.05 Small cell B-cell lymphma, lymph ndes f inguinal regin and lwer limb C83.06 Small cell B-cell lymphma, intrapelvic lymph ndes C83.07 Small cell B-cell lymphma, spleen C83.08 Small cell B-cell lymphma, lymph ndes f multiple sites C83.09 Small cell B-cell lymphma, extrandal and slid rgan sites C83.30 Diffuse large B-cell lymphma unspecified site C83.31 Diffuse large B-cell lymphma, lymph ndes f head, face, and neck Mda Health Plan, Inc. Medical Necessity Criteria Page 8/18

9 C83.32 Diffuse large B-cell lymphma intrathracic lymph ndes C83.33 Diffuse large B-cell lymphma intra-abdminal lymph ndes C83.34 Diffuse large B-cell lymphma lymph ndes f axilla and upper limb C83.35 Diffuse large B-cell lymphma, lymph ndes f inguinal regin and lwer limb C83.36 Diffuse large B-cell lymphma intrapelvic lymph ndes C83.37 Diffuse large B-cell lymphma, spleen C83.38 Diffuse large B-cell lymphma lymph ndes f multiple sites C83.39 Diffuse large B-cell lymphma extrandal and slid rgan sites C91.00 Acute lymphblastic leukemia nt having achieved remissin C91.01 Acute lymphblastic leukemia, in remissin C91.02 Acute lymphblastic leukemia, in relapse D36.0 Benign neplasm f lymph ndes D47.Z2 Castleman disease M05.10 Rheumatid lung disease with rheumatid arthritis f unspecified site M Rheumatid lung disease with rheumatid arthritis f right shulder M Rheumatid lung disease with rheumatid arthritis f left shulder M Rheumatid lung disease with rheumatid arthritis f unspecified shulder M Rheumatid lung disease with rheumatid arthritis f right elbw M Rheumatid lung disease with rheumatid arthritis f left elbw M Rheumatid lung disease with rheumatid arthritis f unspecified elbw M Rheumatid lung disease with rheumatid arthritis f right wrist M Rheumatid lung disease with rheumatid arthritis f left wrist M Rheumatid lung disease with rheumatid arthritis f unspecified wrist M Rheumatid lung disease with rheumatid arthritis f right hand M Rheumatid lung disease with rheumatid arthritis f left hand M Rheumatid lung disease with rheumatid arthritis f unspecified hand M Rheumatid lung disease with rheumatid arthritis f right hip M Rheumatid lung disease with rheumatid arthritis f left hip M Rheumatid lung disease with rheumatid arthritis f unspecified hip M Rheumatid lung disease with rheumatid arthritis f right knee M Rheumatid lung disease with rheumatid arthritis f left knee M Rheumatid lung disease with rheumatid arthritis f unspecified knee M Rheumatid lung disease with rheumatid arthritis f right ankle and ft M Rheumatid lung disease with rheumatid arthritis f left ankle and ft M Rheumatid lung disease with rheumatid arthritis f unspecified ankle and ft M05.19 Rheumatid lung disease with rheumatid arthritis f multiple sites M05.20 Rheumatid vasculitis with rheumatid arthritis f unspecified site M Rheumatid vasculitis with rheumatid arthritis f right shulder M Rheumatid vasculitis with rheumatid arthritis f left shulder M Rheumatid vasculitis with rheumatid arthritis f unspecified shulder Mda Health Plan, Inc. Medical Necessity Criteria Page 9/18

10 M Rheumatid vasculitis with rheumatid arthritis f right elbw M Rheumatid vasculitis with rheumatid arthritis f left elbw M Rheumatid vasculitis with rheumatid arthritis f unspecified elbw M Rheumatid vasculitis with rheumatid arthritis f right wrist M Rheumatid vasculitis with rheumatid arthritis f left wrist M Rheumatid vasculitis with rheumatid arthritis f unspecified wrist M Rheumatid vasculitis with rheumatid arthritis f right hand M Rheumatid vasculitis with rheumatid arthritis f left hand M Rheumatid vasculitis with rheumatid arthritis f unspecified hand M Rheumatid vasculitis with rheumatid arthritis f right hip M Rheumatid vasculitis with rheumatid arthritis f left hip M Rheumatid vasculitis with rheumatid arthritis f unspecified hip M Rheumatid vasculitis with rheumatid arthritis f right knee M Rheumatid vasculitis with rheumatid arthritis f left knee M Rheumatid vasculitis with rheumatid arthritis f unspecified knee M Rheumatid vasculitis with rheumatid arthritis f right ankle and ft M Rheumatid vasculitis with rheumatid arthritis f left ankle and ft M Rheumatid vasculitis with rheumatid arthritis f unspecified ankle and ft M05.29 Rheumatid vasculitis with rheumatid arthritis f multiple sites M05.30 Rheumatid heart disease with rheumatid arthritis f unspecified site M Rheumatid heart disease with rheumatid arthritis f right shulder M Rheumatid heart disease with rheumatid arthritis f left shulder M Rheumatid heart disease with rheumatid arthritis f unspecified shulder M Rheumatid heart disease with rheumatid arthritis f right elbw M Rheumatid heart disease with rheumatid arthritis f left elbw M Rheumatid heart disease with rheumatid arthritis f unspecified elbw M Rheumatid heart disease with rheumatid arthritis f right wrist M Rheumatid heart disease with rheumatid arthritis f left wrist M Rheumatid heart disease with rheumatid arthritis f unspecified wrist M Rheumatid heart disease with rheumatid arthritis f right hand M Rheumatid heart disease with rheumatid arthritis f left hand M Rheumatid heart disease with rheumatid arthritis f unspecified hand M Rheumatid heart disease with rheumatid arthritis f right hip M Rheumatid heart disease with rheumatid arthritis f left hip M Rheumatid heart disease with rheumatid arthritis f unspecified hip M Rheumatid heart disease with rheumatid arthritis f right knee M Rheumatid heart disease with rheumatid arthritis f left knee M Rheumatid heart disease with rheumatid arthritis f unspecified knee M Rheumatid heart disease with rheumatid arthritis f right ankle and ft M Rheumatid heart disease with rheumatid arthritis f left ankle and ft Mda Health Plan, Inc. Medical Necessity Criteria Page 10/18

11 M Rheumatid heart disease with rheumatid arthritis f unspecified ankle and ft M05.39 Rheumatid heart disease with rheumatid arthritis f multiple sites M05.40 Rheumatid mypathy with rheumatid arthritis f unspecified site M Rheumatid mypathy with rheumatid arthritis f right shulder M Rheumatid mypathy with rheumatid arthritis f left shulder M Rheumatid mypathy with rheumatid arthritis f unspecified shulder M Rheumatid mypathy with rheumatid arthritis f right elbw M Rheumatid mypathy with rheumatid arthritis f left elbw M Rheumatid mypathy with rheumatid arthritis f unspecified elbw M Rheumatid mypathy with rheumatid arthritis f right wrist M Rheumatid mypathy with rheumatid arthritis f left wrist M Rheumatid mypathy with rheumatid arthritis f unspecified wrist M Rheumatid mypathy with rheumatid arthritis f right hand M Rheumatid mypathy with rheumatid arthritis f left hand M Rheumatid mypathy with rheumatid arthritis f unspecified hand M Rheumatid mypathy with rheumatid arthritis f right hip M Rheumatid mypathy with rheumatid arthritis f left hip M Rheumatid mypathy with rheumatid arthritis f unspecified hip M Rheumatid mypathy with rheumatid arthritis f right knee M Rheumatid mypathy with rheumatid arthritis f left knee M Rheumatid mypathy with rheumatid arthritis f unspecified knee M Rheumatid mypathy with rheumatid arthritis f right ankle and ft M Rheumatid mypathy with rheumatid arthritis f left ankle and ft M Rheumatid mypathy with rheumatid arthritis f unspecified ankle and ft M05.49 Rheumatid mypathy with rheumatid arthritis f multiple sites M05.50 Rheumatid mypathy with rheumatid arthritis f unspecified sites M Rheumatid plyneurpathy with rheumatid arthritis f right shulder M Rheumatid plyneurpathy with rheumatid arthritis f left shulder M Rheumatid plyneurpathy with rheumatid arthritis f unspecified shulder M Rheumatid plyneurpathy with rheumatid arthritis f right elbw M Rheumatid plyneurpathy with rheumatid arthritis f left elbw M Rheumatid plyneurpathy with rheumatid arthritis f unspecified elbw M Rheumatid plyneurpathy with rheumatid arthritis f right wrist M Rheumatid plyneurpathy with rheumatid arthritis f left wrist M Rheumatid plyneurpathy with rheumatid arthritis f unspecified wrist M Rheumatid plyneurpathy with rheumatid arthritis f right hand M Rheumatid plyneurpathy with rheumatid arthritis f left hand M Rheumatid plyneurpathy with rheumatid arthritis f unspecified hand M Rheumatid plyneurpathy with rheumatid arthritis f right hip M Rheumatid plyneurpathy with rheumatid arthritis f left hip Mda Health Plan, Inc. Medical Necessity Criteria Page 11/18

12 M Rheumatid plyneurpathy with rheumatid arthritis f unspecified hip M Rheumatid plyneurpathy with rheumatid arthritis f right knee M Rheumatid plyneurpathy with rheumatid arthritis f left knee M Rheumatid plyneurpathy with rheumatid arthritis f unspecified knee M Rheumatid plyneurpathy with rheumatid arthritis f right ankle and ft M Rheumatid plyneurpathy with rheumatid arthritis f left ankle and ft M Rheumatid plyneurpathy with rheumatid arthritis f unspecified ankle and ft M05.59 Rheumatid plyneurpathy with rheumatid arthritis f multiple sites M05.60 Rheumatid arthritis f unspecified site with invlvement f ther rgans and systems M Rheumatid arthritis f right shulder with invlvement f ther rgans and systems M Rheumatid arthritis f left shulder with invlvement f ther rgans and systems M Rheumatid arthritis f unspecified shulder with invlvement f ther rgans and systems M Rheumatid arthritis f right elbw with invlvement f ther rgans and systems M Rheumatid arthritis f left elbw with invlvement f ther rgans and systems M Rheumatid arthritis f unspecified elbw with invlvement f ther rgans and systems M Rheumatid arthritis f right wrist with invlvement f ther rgans and systems M Rheumatid arthritis f left wrist with invlvement f ther rgans and systems M Rheumatid arthritis f unspecified wrist with invlvement f ther rgans and systems M Rheumatid arthritis f right hand with invlvement f ther rgans and systems M Rheumatid arthritis f left hand with invlvement f ther rgans and systems M Rheumatid arthritis f unspecified hand with invlvement f ther rgans and systems M Rheumatid arthritis f right hip with invlvement f ther rgans and systems M Rheumatid arthritis f left hip with invlvement f ther rgans and systems M Rheumatid arthritis f unspecified hip with invlvement f ther rgans and systems M Rheumatid arthritis f right knee with invlvement f ther rgans and systems M Rheumatid arthritis f left knee with invlvement f ther rgans and systems M Rheumatid arthritis f unspecified knee with invlvement f ther rgans and systems M Rheumatid arthritis f right ankle and ft with invlvement f ther rgans and systems M Rheumatid arthritis f left ankle and ft with invlvement f ther rgans and systems M Rheumatid arthritis f unspecified ankle and ft with invlvement f ther rgans and systems M05.69 Rheumatid arthritis f multiple sites with invlvement f ther rgans and systems M05.70 Rheumatid arthritis with rheumatid factr f unspecified site withut rgan r systems M Rheumatid arthritis with rheumatid factr f right shulder withut rgan r systems M Rheumatid arthritis with rheumatid factr f left shulder withut rgan r systems invlvement M Rheumatid arthritis with rheumatid factr f unspecified shulder withut rgan r systems M Rheumatid arthritis with rheumatid factr f right elbw withut rgan r systems invlvement M Rheumatid arthritis with rheumatid factr f left elbw withut rgan r systems invlvement M Rheumatid arthritis with rheumatid factr f unspecified elbw withut rgan r systems M Rheumatid arthritis with rheumatid factr f right wrist withut rgan r systems invlvement M Rheumatid arthritis with rheumatid factr f left wrist withut rgan r systems invlvement Mda Health Plan, Inc. Medical Necessity Criteria Page 12/18

13 M Rheumatid arthritis with rheumatid factr f unspecified wrist withut rgan r systems M Rheumatid arthritis with rheumatid factr f right hand withut rgan r systems invlvement M Rheumatid arthritis with rheumatid factr f left hand withut rgan r systems invlvement M Rheumatid arthritis with rheumatid factr f unspecified hand withut rgan r systems M Rheumatid arthritis with rheumatid factr f right hip withut rgan r systems invlvement M Rheumatid arthritis with rheumatid factr f left hip withut rgan r systems invlvement M Rheumatid arthritis with rheumatid factr f unspecified hip withut rgan r systems M Rheumatid arthritis with rheumatid factr f right knee withut rgan r systems invlvement M Rheumatid arthritis with rheumatid factr f left knee withut rgan r systems invlvement M Rheumatid arthritis with rheumatid factr f unspecified knee withut rgan r systems M Rheumatid arthritis with rheumatid factr f right ankle and ft withut rgan r systems M Rheumatid arthritis with rheumatid factr f left ankle and ft withut rgan r systems M Rheumatid arthritis with rheumatid factr f unspecified ankle and wrist withut rgan r M05.79 Rheumatid arthritis with rheumatid factr f multiple sites withut rgan r systems M05.80 Other rheumatid arthritis with rheumatid factr f unspecified site M Other rheumatid arthritis with rheumatid factr f right shulder M Other rheumatid arthritis with rheumatid factr f left shulder M Other rheumatid arthritis with rheumatid factr f unspecified shulder M Other rheumatid arthritis with rheumatid factr f right elbw M Other rheumatid arthritis with rheumatid factr f left elbw M Other rheumatid arthritis with rheumatid factr f unspecified elbw M Other rheumatid arthritis with rheumatid factr f right wrist M Other rheumatid arthritis with rheumatid factr f left wrist M Other rheumatid arthritis with rheumatid factr f unspecified wrist M Other rheumatid arthritis with rheumatid factr f right hand M Other rheumatid arthritis with rheumatid factr f left hand M Other rheumatid arthritis with rheumatid factr f unspecified hand M Other rheumatid arthritis with rheumatid factr f right hip M Other rheumatid arthritis with rheumatid factr f left hip M Other rheumatid arthritis with rheumatid factr f unspecified hip M Other rheumatid arthritis with rheumatid factr f right knee M Other rheumatid arthritis with rheumatid factr f left knee M Other rheumatid arthritis with rheumatid factr f unspecified knee M Other rheumatid arthritis with rheumatid factr f right ankle and ft M Other rheumatid arthritis with rheumatid factr f left ankle and ft M Other rheumatid arthritis with rheumatid factr f unspecified ankle and ft M05.89 Other rheumatid arthritis with rheumatid factr f multiple sites M05.9 Rheumatid arthritis with rheumatid factr, unspecified M06.00 Rheumatid arthritis withut rheumatid factr, unspecified site M Rheumatid arthritis withut rheumatid factr, unspecified shulder Mda Health Plan, Inc. Medical Necessity Criteria Page 13/18

14 M Rheumatid arthritis withut rheumatid factr, right elbw M Rheumatid arthritis withut rheumatid factr, left elbw M Rheumatid arthritis withut rheumatid factr, unspecified elbw M Rheumatid arthritis withut rheumatid factr, right wrist M Rheumatid arthritis withut rheumatid factr, left wrist M Rheumatid arthritis withut rheumatid factr, unspecified wrist M Rheumatid arthritis withut rheumatid factr, right hand M Rheumatid arthritis withut rheumatid factr, left hand M Rheumatid arthritis withut rheumatid factr, unspecified hand M Rheumatid arthritis withut rheumatid factr, right hip M Rheumatid arthritis withut rheumatid factr, left hip M Rheumatid arthritis withut rheumatid factr, unspecified hip M Rheumatid arthritis withut rheumatid factr, right knee M Rheumatid arthritis withut rheumatid factr, left knee M Rheumatid arthritis withut rheumatid factr, unspecified knee M Rheumatid arthritis withut rheumatid factr, right ankle and ft M Rheumatid arthritis withut rheumatid factr, left ankle and ft M Rheumatid arthritis withut rheumatid factr, unspecified ankle and ft M06.4 Inflammatry plyarthrpathy M06.08 Rheumatid arthritis withut rheumatid factr, vertebrae M06.09 Rheumatid arthritis withut rheumatid factr, multiple sites M06.80 Other specified rheumatid arthritis, unspecified site M Other specified rheumatid arthritis, right shulder M Other specified rheumatid arthritis, left shulder M Other specified rheumatid arthritis, unspecified shulder M Other specified rheumatid arthritis, right elbw M Other specified rheumatid arthritis, left elbw M Other specified rheumatid arthritis, unspecified elbw M Other specified rheumatid arthritis, right wrist M Other specified rheumatid arthritis, left wrist M Other specified rheumatid arthritis, unspecified wrist M Other specified rheumatid arthritis, right hand M Other specified rheumatid arthritis, left hand M Other specified rheumatid arthritis, unspecified hand M Other specified rheumatid arthritis, right hip M Other specified rheumatid arthritis, left hip M Other specified rheumatid arthritis, unspecified hip M Other specified rheumatid arthritis, right knee M Other specified rheumatid arthritis, left knee M Other specified rheumatid arthritis, unspecified knee Mda Health Plan, Inc. Medical Necessity Criteria Page 14/18

15 M Other specified rheumatid arthritis, right ankle and ft M Other specified rheumatid arthritis, left ankle and ft M Other specified rheumatid arthritis, unspecified ankle and ft M06.88 Other specified rheumatid arthritis, vertebrae M06.89 Other specified rheumatid arthritis, multiple sites M06.9 Rheumatid arthritis, unspecified M08.00 Unspecified juvenile rheumatid arthritis f unspecified site M Unspecified juvenile rheumatid arthritis, right shulder M Unspecified juvenile rheumatid arthritis, left shulder M Unspecified juvenile rheumatid arthritis, unspecified shulder M Unspecified juvenile rheumatid arthritis, right elbw M Unspecified juvenile rheumatid arthritis, left elbw M Unspecified juvenile rheumatid arthritis, unspecified elbw M Unspecified juvenile rheumatid arthritis, right wrist M Unspecified juvenile rheumatid arthritis, left wrist M Unspecified juvenile rheumatid arthritis, unspecified wrist M Unspecified juvenile rheumatid arthritis, right hand M Unspecified juvenile rheumatid arthritis, left hand M Unspecified juvenile rheumatid arthritis, unspecified hand M Unspecified juvenile rheumatid arthritis, right hip M Unspecified juvenile rheumatid arthritis, left hip M Unspecified juvenile rheumatid arthritis, unspecified hip M Unspecified juvenile rheumatid arthritis, right knee M Unspecified juvenile rheumatid arthritis, left knee M Unspecified juvenile rheumatid arthritis, unspecified knee M Unspecified juvenile rheumatid arthritis, right ankle and ft M Unspecified juvenile rheumatid arthritis, left ankle and ft M Unspecified juvenile rheumatid arthritis, unspecified ankle and ft M08.08 Unspecified juvenile rheumatid arthritis, vertebrae M08.09 Unspecified juvenile rheumatid arthritis, multiple sites M08.20 Juvenile rheumatid arthritis with systemic nset, unspecified site M Juvenile rheumatid arthritis with systemic nset, right shulder M Juvenile rheumatid arthritis with systemic nset, left shulder M Juvenile rheumatid arthritis with systemic nset, unspecified shulder M Juvenile rheumatid arthritis with systemic nset, right elbw M Juvenile rheumatid arthritis with systemic nset, left elbw M Juvenile rheumatid arthritis with systemic nset, unspecified elbw M Juvenile rheumatid arthritis with systemic nset, right wrist M Juvenile rheumatid arthritis with systemic nset, left wrist M Juvenile rheumatid arthritis with systemic nset, unspecified wrist Mda Health Plan, Inc. Medical Necessity Criteria Page 15/18

16 M Juvenile rheumatid arthritis with systemic nset, right hand M Juvenile rheumatid arthritis with systemic nset, left hand M Juvenile rheumatid arthritis with systemic nset, unspecified hand M Juvenile rheumatid arthritis with systemic nset, right hip M Juvenile rheumatid arthritis with systemic nset, left hip M Juvenile rheumatid arthritis with systemic nset, unspecified hip M Juvenile rheumatid arthritis with systemic nset, right knee M Juvenile rheumatid arthritis with systemic nset, left knee M Juvenile rheumatid arthritis with systemic nset, unspecified knee M Juvenile rheumatid arthritis with systemic nset, right ankle and ft M Juvenile rheumatid arthritis with systemic nset, left ankle and ft M Juvenile rheumatid arthritis with systemic nset, unspecified ankle and ft M08.28 Juvenile rheumatid arthritis with systemic nset, vertebrae M08.29 Juvenile rheumatid arthritis with systemic nset, multiple sites M08.3 Juvenile rheumatid plyarthritis (sernegative) M08.40 Pauciarticular juvenile rheumatid arthritis, unspecified site M Pauciarticular juvenile rheumatid arthritis, right shulder M Pauciarticular juvenile rheumatid arthritis, left shulder M Pauciarticular juvenile rheumatid arthritis, unspecified shulder M Pauciarticular juvenile rheumatid arthritis, right elbw M Pauciarticular juvenile rheumatid arthritis, left elbw M Pauciarticular juvenile rheumatid arthritis, unspecified elbw M Pauciarticular juvenile rheumatid arthritis, right wrist M Pauciarticular juvenile rheumatid arthritis, left wrist M Pauciarticular juvenile rheumatid arthritis, unspecified wrist M Pauciarticular juvenile rheumatid arthritis, right hand M Pauciarticular juvenile rheumatid arthritis, left hand M Pauciarticular juvenile rheumatid arthritis, unspecified hand M Pauciarticular juvenile rheumatid arthritis, right hip M Pauciarticular juvenile rheumatid arthritis, left hip M Pauciarticular juvenile rheumatid arthritis, unspecified hip M Pauciarticular juvenile rheumatid arthritis, right knee M Pauciarticular juvenile rheumatid arthritis, left knee M Pauciarticular juvenile rheumatid arthritis, unspecified knee M Pauciarticular juvenile rheumatid arthritis, right ankle and ft M Pauciarticular juvenile rheumatid arthritis, left ankle and ft M Pauciarticular juvenile rheumatid arthritis, unspecified ankle and ft M08.48 Pauciarticular juvenile rheumatid arthritis, vertebrae M08.80 Other juvenile arthritis, unspecified site M Other juvenile arthritis, right shulder Mda Health Plan, Inc. Medical Necessity Criteria Page 16/18

17 M Other juvenile arthritis, left shulder M Other juvenile arthritis, unspecified shulder M Other juvenile arthritis, right elbw M Other juvenile arthritis, left elbw M Other juvenile arthritis, unspecified elbw M Other juvenile arthritis, right wrist M Other juvenile arthritis, left wrist M Other juvenile arthritis, unspecified wrist M Other juvenile arthritis, right hand M Other juvenile arthritis, left hand M Other juvenile arthritis, unspecified hand M Other juvenile arthritis, right hip M Other juvenile arthritis, left hip M Other juvenile arthritis, unspecified hip M Other juvenile arthritis, right knee M Other juvenile arthritis, left knee M Other juvenile arthritis, unspecified knee M Other juvenile arthritis, right ankle and ft M Other juvenile arthritis, left ankle and ft M Other juvenile arthritis, unspecified ankle and ft M08.88 Other juvenile arthritis, ther specified site M08.89 Other juvenile arthritis, multiple sites M08.90 Juvenile arthritis, unspecified, unspecified site M Juvenile arthritis, unspecified, right shulder M Juvenile arthritis, unspecified, left shulder M Juvenile arthritis, unspecified, unspecified shulder M Juvenile arthritis, unspecified, right elbw M Juvenile arthritis, unspecified, left elbw M Juvenile arthritis, unspecified, unspecified elbw M Juvenile arthritis, unspecified, right wrist M Juvenile arthritis, unspecified, left wrist M Juvenile arthritis, unspecified, unspecified wrist M Juvenile arthritis, unspecified, right hand M Juvenile arthritis, unspecified, left hand M Juvenile arthritis, unspecified, unspecified hand M Juvenile arthritis, unspecified, right hip M Juvenile arthritis, unspecified, left hip M Juvenile arthritis, unspecified, unspecified hip M Juvenile arthritis, unspecified, right knee M Juvenile arthritis, unspecified, left knee Mda Health Plan, Inc. Medical Necessity Criteria Page 17/18

18 M Juvenile arthritis, unspecified, unspecified knee M Juvenile arthritis, unspecified, right ankle and ft M Juvenile arthritis, unspecified, left ankle and ft M Juvenile arthritis, unspecified, unspecified ankle and ft M08.98 Juvenile arthritis, unspecified, vertebrae M08.99 Juvenile arthritis, unspecified, multiple sites R59.0 Lcalized enlarged lymph ndes R59.1 Generalized enlarged lymph ndes R59.9 Enlarged lymph ndes, unspecified Z85.72 Persnal histry f nn-hdgkin lymphmas Appendix 2 Centers fr Medicare and Medicaid Services (CMS) Medicare cverage fr utpatient (Part B) drugs is utlined in the Medicare Benefit Plicy Manual (Pub ), Chapter 15, 50 Drugs and Bilgicals. In additin, Natinal Cverage Determinatin (NCD) and Lcal Cverage Determinatins (LCDs) may exist and cmpliance with these plicies is required where applicable. They can be fund at: Additinal indicatins may be cvered at the discretin f the health plan. Medicare Part B Cvered Diagnsis Cdes (applicable t existing NCD/LCD): N/A Medicare Part B Administrative Cntractr (MAC) Jurisdictins Jurisdictin Applicable State/US Territry Cntractr E (1) CA, HI, NV, AS, GU, CNMI Nridian Healthcare Slutins, LLC F (2 & 3) AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ Nridian Healthcare Slutins, LLC 5 KS, NE, IA, MO Wiscnsin Physicians Service Insurance Crp (WPS) 6 MN, WI, IL Natinal Gvernment Services, Inc. (NGS) H (4 & 7) LA, AR, MS, TX, OK, CO, NM Nvitas Slutins, Inc. 8 MI, IN Wiscnsin Physicians Service Insurance Crp (WPS) N (9) FL, PR, VI First Cast Service Optins, Inc. J (10) TN, GA, AL Palmett GBA, LLC M (11) NC, SC, WV, VA (excluding belw) Palmett GBA, LLC L (12) DE, MD, PA, NJ, DC (includes Arlingtn & Fairfax cunties and the city f Alexandria in VA) K (13 & 14) NY, CT, MA, RI, VT, ME, NH Nvitas Slutins, Inc. Natinal Gvernment Services, Inc. (NGS) 15 KY, OH CGS Administratrs, LLC Mda Health Plan, Inc. Medical Necessity Criteria Page 18/18

Orencia (abatacept) Document Number: MODA-0091

Orencia (abatacept) Document Number: MODA-0091 Orencia (abatacept) Dcument Number: MODA-0091 Last Review Date: 09/19/2017 Date f Origin: 07/02/2010 Dates Reviewed: 07/2010, 09/2010, 12/2010, 02/15/11, 03/2011, 06/2011, 09/2011, 12/2011, 03/2012, 06/2012,

More information

Kadcyla (ado-trastuzumab emtansine) Document Number: IC-0092

Kadcyla (ado-trastuzumab emtansine) Document Number: IC-0092 Kadcyla (ad-trastuzumab emtansine) Dcument Number: IC-0092 Last Review Date: 2/6/2018 Date f Origin: 05/16/2013 Dates Reviewed: 7/2013, 11/2013, 12/2013, 3/2014, 6/2014, 9/2014, 12/2014, 5/2015, 8/2015,

More information

Perjeta (pertuzumab) Document Number: IC I. Length of Authorization. Dosing Limits. Initial Approval Criteria

Perjeta (pertuzumab) Document Number: IC I. Length of Authorization. Dosing Limits. Initial Approval Criteria Perjeta (pertuzumab) Last Review Date: 11/21/2017 Date f Origin: 11/01/2012 Dcument Number: IC-0096 Dates Reviewed: 12/2012, 3/2013, 6/2013, 9/2013, 11/2013, 12/2013, 3/2014, 6/2014, 9/2014, 12/2014, 3/2015,

More information

Yescarta (axicabtagene ciloleucel) (Intravenous)

Yescarta (axicabtagene ciloleucel) (Intravenous) Yescarta (axicabtagene cilleucel) (Intravenus) Last Review Date: 10/31/2017 Date f Origin: 10/31/2017 Dates Reviewed: 10/2017 Dcument Number: IC-0333 I. Length f Authrizatin Cverage will be prvided fr

More information

Mylotarg (gemtuzumab ozogamicin) (Intravenous)

Mylotarg (gemtuzumab ozogamicin) (Intravenous) Myltarg (gemtuzumab zgamicin) (Intravenus) Last Review Date: 09/19/2017 Date f Origin: 09/19/2017 Dates Reviewed: 09/2017 Dcument Number: IC-0320 I. Length f Authrizatin Newly-Diagnsed AML De nv disease

More information

Sandostatin LAR (octreotide suspension) Document Number: IC-0111

Sandostatin LAR (octreotide suspension) Document Number: IC-0111 Sandstatin LAR (ctretide suspensin) Dcument Number: IC-0111 Last Review Date: 02/06/2018 Date f Origin: 06/21/2011 Dates Reviewed: 09/2011, 12/2011, 03/2012, 06/2012, 09/2012, 12/2012, 03/2013, 06/2013,

More information

Rituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous)

Rituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous) Rituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous) Document Number: IC-0322 Last Review Date: 02/06/2018 Date of Origin: 7/20/2010 Dates Reviewed: 09/2010, 12/2010, 02/2011, 03/2011, 05/2011,

More information

Abraxane (paclitaxel protein-bound particles) (Intravenous)

Abraxane (paclitaxel protein-bound particles) (Intravenous) Abraxane (paclitaxel prtein-bund particles) (Intravenus) Last Review Date: 5/30/2017 Date f Origin: 10/17/2008 Dcument Number: IC-0001 Dates Reviewed: 06/2009, 12/2009, 07/2010, 09/2010, 12/2010, 03/2011,

More information

Rituxan (rituximab) Document Number: IC-0109

Rituxan (rituximab) Document Number: IC-0109 Rituxan (rituximab) Dcument Number: IC-0109 Last Review Date: 10/31/2017 Date f Origin: 7/20/2010 Dates Reviewed: 09/2010, 12/2010, 02/2011, 03/2011, 05/2011, 06/2011, 09/2011, 12/2011, 03/2012, 06/2012,

More information

Velcade (bortezomib) Document Number: IC-0137

Velcade (bortezomib) Document Number: IC-0137 Velcade (bortezomib) Document Number: IC-0137 Last Review Date: 11/21/2017 Date of Origin: 11/28/2011 Dates Reviewed: 12/2011, 03/2012, 06/2012, 09/2012, 12/2012, 03/2013, 06/2013, 09/2013, 12/2013, 03/2014,

More information

Rituxan (rituximab) Effective Date: 10/01/2015. Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage

Rituxan (rituximab) Effective Date: 10/01/2015. Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Rituxan (rituximab) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Effective Date: 10/01/2015 POLICY A. INDICATIONS The indicatins belw including FDA-apprved indicatins and cmpendial uses

More information

Krystexxa (pegloticase) Document Number: IC-0158

Krystexxa (pegloticase) Document Number: IC-0158 Krystexxa (pegloticase) Document Number: IC-0158 Last Review Date: 06/27/2017 Date of Origin: 02/07/20103 Dates Reviewed: 11/2013, 08/2014, 07/2015, 07/2016, 09/2016, 12/2016, 03/2017, 06/2017 I. Length

More information

Imfinzi (durvalumab) (Intravenous)

Imfinzi (durvalumab) (Intravenous) Imfinzi (durvalumab) (Intravenous) Last Review Date: 09/05/2018 Date of Origin: 05/30/2017 Dates Reviewed: 05/2017, 08/2017, 11/2017, 02/2018, 05/2018, 09/2018 Document Number: IC-0301 I. Length of Authorization

More information

Tecentriq (atezolizumab) (Intravenous)

Tecentriq (atezolizumab) (Intravenous) Tecentriq (atezolizumab) (Intravenous) Last Review Date: 06/01/2018 Date of Origin: 06/28/2016 Document Number: IC-0278 Dates Reviewed: 06/2016, 08/2016, 10/2016, 02/2017, 04/2017, 08/2017, 11/2017, 02/2018,

More information

Drug Therapy Guidelines

Drug Therapy Guidelines Drug Therapy Guidelines Orencia (abatacept) Applicable Medical Benefit x Effective: 2/21/18 Pharmacy- Frmulary 1 x Next Review: 12/18 Pharmacy- Frmulary 2 x Date f Origin: 11/28/06 Pharmacy- Frmulary 3/Exclusive

More information

Soliris (eculizumab) Document Number: MODA-0114

Soliris (eculizumab) Document Number: MODA-0114 Sliris (eculizumab) Dcument Number: MODA-0114 Last Review Date: 9/19/2017 Date f Origin: 06/21/2011 Dates Reviewed: 09/2011, 12/2011, 03/2012, 06/2012, 09/2012, 12/2012, 03/2013, 03/2014, 06/2014, 09/2014,

More information

Ilaris (canakinumab) (Subcutaneous)

Ilaris (canakinumab) (Subcutaneous) Ilaris (canakinumab) (Subcutaneous) Last Review Date: 08/02/2018 Date of Origin: 11/07/2013 Dates Reviewed: 08/2014, 07/2015, 07/2016, 10/2016, 10/2017, 08/2018 Document Number: IC-0177 I. Length of Authorization

More information

Dates Reviewed: 12/2012, 3/2013, 6/2013, 9/2013, 11/2013, 12/2013, 3/2014, 6/2014, 9/2014, 12/2014,

Dates Reviewed: 12/2012, 3/2013, 6/2013, 9/2013, 11/2013, 12/2013, 3/2014, 6/2014, 9/2014, 12/2014, Perjeta (pertuzumab) Last Review Date: 5/30/2017 Date of Origin: 11/01/2012 Document Number: IC-0096 Dates Reviewed: 12/2012, 3/2013, 6/2013, 9/2013, 11/2013, 12/2013, 3/2014, 6/2014, 9/2014, 12/2014,

More information

Eylea (aflibercept) Document Number: IC-0026

Eylea (aflibercept) Document Number: IC-0026 Eylea (aflibercept) Document Number: IC-0026 Last Review Date: 3/1/2018 Date of Origin: 02/07/2013 Dates Reviewed: 03/07/2013, 06/2013, 09/2013, 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015, 04/2015,

More information

Intravitreal Avastin (Bevacizumab)

Intravitreal Avastin (Bevacizumab) Intravitreal Avastin (Bevacizumab) Date of Origin: 10/18/2018 Last Review Date: 10/18/2018 Effective Date: 10/18/2018 Dates Reviewed: 10/2018 Developed By: Medical Criteria Committee I. Length of Authorization

More information

Simponi ARIA (golimumab) (Intravenous)

Simponi ARIA (golimumab) (Intravenous) Simponi ARIA (golimumab) (Intravenous) Last Review Date: 10/31/2017 Date of Origin: 09/05/2013 Document Number: MODA-0176 Dates Reviewed: 12/2013, 8/2014, 3/2015, 6/2015, 9/2015, 12/2015, 3/2016, 6/2016,

More information

Folotyn (pralatrexate)

Folotyn (pralatrexate) Fltyn (pralatrexate) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/2018TBD03/01/2017 POLICY A. INDICATIONS The indicatins

More information

Must be used as initial treatment as a single agent with sequential chemoradiation

Must be used as initial treatment as a single agent with sequential chemoradiation Erbitux (cetuximab) Dcument Number: IC-0038 Last Review Date: 11/21/2017 Date f Origin: 12/22/2009 Dates Reviewed: 07/2010, 09/2010, 12/2010, 03/2011, 06/2011, 09/2011, 12/2011, 03/2012, 06/2012, 09/2012,

More information

Erythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) Related Medical Guideline Off-Label Use of FDA-Approved Drugs and Biologicals

Erythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) Related Medical Guideline Off-Label Use of FDA-Approved Drugs and Biologicals (Subcutaneus/Intravenus) Last Review Date: January 1, 2019 Number: MG.MM.PH.80 *NON-DIALYSIS* Medical Guideline Disclaimer C All rights reserved. The treating physician r primary care prvider must submit

More information

Cyramza (ramucirumab) (Intravenous)

Cyramza (ramucirumab) (Intravenous) Cyramza (ramucirumab) (Intravenous) Document Number: IC 0199 Last Review Date: 5/1/2018 Date of Origin: 06/24/2014 Dates Reviewed: 09/2014, 01/2015, 05/2015, 11/2015, 04/2016, 08/2016, 11/2016, 05/2017,

More information

SCIG: Hizentra, Gammagard Liquid, Gamunex -C, Gammaked, Hyqvia, Cuvitru (immune globulin SQ)

SCIG: Hizentra, Gammagard Liquid, Gamunex -C, Gammaked, Hyqvia, Cuvitru (immune globulin SQ) SCIG: Hizentra, Gammagard Liquid, Gamunex -C, Gammaked, Hyqvia, Cuvitru (immune glbulin SQ) Dcument Number: IC-0059 Last Review Date: 04/03/2018 Date f Origin: 7/20/2010 Dates Reviewed: 9/2010, 12/2010,

More information

Drug Therapy Guidelines

Drug Therapy Guidelines Applicable* Medical Benefit x Effective: 2/15/19 Pharmacy- Frmulary 1 Next Review: 12/19 Pharmacy- Frmulary 2 Date f Origin: 4/1/05 Pharmacy- Frmulary 3/Exclusive Review Dates: 4/1/05, 2/1/06, 10/15/06,

More information

Document Number: IC I. Length of Authorization. Dosing Limits

Document Number: IC I. Length of Authorization. Dosing Limits Hyaluronic Acid Derivatives: Durolane, Euflexxa, Gel-One, GelSyn-3, GenVisc 850, Hyalgan, Hymovis, Monovisc, Orthovisc, Supartz/Supartz FX, Synojoynt, Synvisc, & Synvisc-One, TriVisc, Visco-3 (Intra-articular)

More information

Erythropoiesis Stimulating Agents (ESAs): Epogen/Procrit (epoetin alfa) (Subcutaneous/Intravenous)

Erythropoiesis Stimulating Agents (ESAs): Epogen/Procrit (epoetin alfa) (Subcutaneous/Intravenous) (Subcutaneus/Intravenus) Last Review Date: January 1, 2019 Number: MG.MM.PH.81 Medical Guideline Disclaimer C All rights reserved. The treating physician r primary care prvider must submit t EmblemHealth

More information

Opdivo (nivolumab) (Intravenous)

Opdivo (nivolumab) (Intravenous) Opdiv (nivlumab) (Intravenus) Last Review Date: 1/03/2018 Date f Origin: 01/06/2015 Dcument Number: IC-0226 Dates Reviewed: 03/2015, 07/2015, 10/2015, 11/2015, 02/2016, 05/2016, 08/2016, 10/2016, 11/2016,

More information

Request for Prior Authorization for Click here to enter text. Website Form Submit request via: Fax

Request for Prior Authorization for Click here to enter text. Website Form   Submit request via: Fax Request fr Prir Authrizatin fr Click here t enter text. Website Frm www.highmarkhealthptins.cm Submit request via: Fax - 1-855-476-4158 Updated: 05/2018 DMMA Apprved: 05/2018 All requests fr Intravenus

More information

XX Abraxane 100 MG SUSR (CELGENE CORP)

XX Abraxane 100 MG SUSR (CELGENE CORP) Plicy Medical Plicy Manual Apprved: D Nt Implement Until 1/31/19 Paclitaxel (Prtein-Bund) NDC CODE(S) 68817-0134-XX Abraxane 100 MG SUSR (CELGENE CORP) DESCRIPTION Paclitaxel is a natural prduct with antitumr

More information

All indications: 60 billable units every 6 months. Giant Cell Tumor of Bone; Hypercalcemia of malignancy

All indications: 60 billable units every 6 months. Giant Cell Tumor of Bone; Hypercalcemia of malignancy Last Review Date: January 1, 2019 Number: MG.MM.PH.100 Medical Guideline Disclaimer C All rights reserved. The treating physician r primary care prvider must submit t EmblemHealth the clinical evidence

More information

Yervoy (ipilmumab) Last Review Date: 03/25/2014 Date of Origin: 11/28/2011. Prior Auth Available: Post-Service Edit:

Yervoy (ipilmumab) Last Review Date: 03/25/2014 Date of Origin: 11/28/2011. Prior Auth Available: Post-Service Edit: Yervoy (ipilmumab) Date of Origin: 11/28/2011 Prior Auth Available: Post-Service Edit: Dates Reviewed: 12/13/2011, 03/2012, 06/19/2012, 09/06/2012, 12/06/2012, 05/16/2013, 06/06/2013, 09/05/2013, 12/05/2013,

More information

Soliris (eculizumab) (Intravenous)

Soliris (eculizumab) (Intravenous) Sliris (eculizumab) (Intravenus) Last Review Date: 02/04/2019 Date f Origin: 06/21/2011 Dcument Number: MODA-0114 Dates Reviewed: 09/2011, 12/2011, 03/2012, 06/2012, 09/2012, 12/2012, 03/2013, 03/2014,

More information

XX Abraxane 100 MG SUSR (CELGENE CORP

XX Abraxane 100 MG SUSR (CELGENE CORP Medical Manual Apprved Revised: D Nt Implement until 6/30/2019 Paclitaxel (Prtein-Bund) NDC CODE(S) 68817-0134-XX Abraxane 100 MG SUSR (CELGENE CORP DESCRIPTION Paclitaxel is a natural prduct with antitumr

More information

New Exception Status Benefits

New Exception Status Benefits FEBRUARY 2019 Nva Sctia Frmulary Updates New Exceptin Status Benefits Prcysbi (cysteamine bitartrate) Nucala (meplizumab) Ocaliva (betichlic acid) Ravicti (glycerl phenylbutyrate) Taltz (ixekizumab) Criteria

More information

o Prostanoids/prostacyclin therapies (oral and inhaled) o Inhaled agents: Ventavis, Tyvaso Page 1 of 5 Revised 02/17/17

o Prostanoids/prostacyclin therapies (oral and inhaled) o Inhaled agents: Ventavis, Tyvaso Page 1 of 5 Revised 02/17/17 Request fr Prir Authrizatin Pulmnary Arterial Hypertensin (PAH) Agents (Oral and Inhaled) Website Frm www.highmarkhealthptins.cm Submit request via: Fax - 1-855-476-4158 All requests fr Pulmnary Arterial

More information

Colony Stimulating Factors: Zarxio (filgrastim sndz) (Subcutaneous/Intravenous)

Colony Stimulating Factors: Zarxio (filgrastim sndz) (Subcutaneous/Intravenous) Colony Stimulating Factors: Zarxio (filgrastim sndz) (Subcutaneous/Intravenous) Document Number: IC 0245 Last Review Date: 5/1/2018 Date of Origin: 03/31/2015 Dates Reviewed: 03/2015, 05/2015, 08/2015,

More information

XX Keytruda 100 MG/4ML SOLN (MERCK SHARP & DOHME)

XX Keytruda 100 MG/4ML SOLN (MERCK SHARP & DOHME) Plicy Medical Plicy Manual Apprved: D Nt Implement Until 1/31/19 Pembrlizumab NDC CODE(S) 00006-3026-XX Keytruda 100 MG/4ML SOLN (MERCK SHARP & DOHME) DESCRIPTION Pembrlizumab is a human prgrammed death

More information

Cardiac Rehabilitation Services

Cardiac Rehabilitation Services Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin

More information

Trelstar (triptorelin) (Intramuscular)

Trelstar (triptorelin) (Intramuscular) Trelstar (triptorelin) (Intramuscular) Last Review Date: 02/06/2018 Date of Origin: 11/28/2011 Document Number: IC-0131 Dates Reviewed: 12/2011, 03/2012, 06/19/2012, 09/2012, 12/2012, 03/2013, 06/2013,

More information

Subject: Abatacept (Orencia ) Injection and Infusion

Subject: Abatacept (Orencia ) Injection and Infusion 09-J0000-67 Original Effective Date: 06/15/07 Reviewed: 09/12/18 Revised: 10/15/18 Subject: Abatacept (Orencia ) Injectin and Infusin THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,

More information

Trelstar Depot (triptorelin)

Trelstar Depot (triptorelin) Dates Reviewed: 12/13/2011, 03/2012, 06/19/2012, 09/06/2012, 12/06/2012, 03/07/2013, 06/06/2013, Date of Origin: 11/28/2011 09/05/2013, 12/05/2013, 03/25/2014 Prior Auth Available: Post-service edit: The

More information

Colony Stimulating Factors: Nivestym (filgrastim-aafi) (Subcutaneous/Intravenous)

Colony Stimulating Factors: Nivestym (filgrastim-aafi) (Subcutaneous/Intravenous) Colony Stimulating Factors: Nivestym (filgrastim-aafi) (Subcutaneous/Intravenous) Document Number: MODA-0375 Last Review Date: 08/06/2018 Date of Origin: 08/06/2018 Dates Reviewed: 08/2018 I. Length of

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY Plicy Name: Plicy Number: Respnsible Department(s): CLINICAL MEDICAL POLICY Supervised Exercise Therapy fr Peripheral Artery Disease (PAD) MP-077-MD-DE Medical Management Prvider Ntice Date: 01/15/2019

More information

Referral Criteria: Inflammation of the Spine Feb

Referral Criteria: Inflammation of the Spine Feb Referral Criteria: Inflammatin f the Spine Feb 2019 1 5.7. Inflammatin f the Spine Backgrund Ankylsing spndylitis and axial spndylarthrpathy are fund in arund 0.3-1.2% f the ppulatin. Spndylarthritis encmpasses

More information

Actemra. Actemra (tocilizumab) Description

Actemra. Actemra (tocilizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.12 Subject: Actemra Page: 1 of 13 Last Review Date: September 20, 2018 Actemra Description Actemra

More information

Drug Therapy Guidelines

Drug Therapy Guidelines Applicable Medical Benefit x Effective: 5/1/18 Pharmacy- Frmulary 1 x Next Review: 3/18 Pharmacy- Frmulary 2 x Date f Origin: 4/99 Gnadtrpin-Releasing Hrmne Agnists- Eligard, Luprn, Luprn-Dept, Luprn Dept-Ped,

More information

My Symptoms and Medical History for Adult Chronic Immune Thrombocytopenia (ITP)

My Symptoms and Medical History for Adult Chronic Immune Thrombocytopenia (ITP) My Symptms and Medical Histry fr Adult Chrnic Immune Thrmbcytpenia (ITP) Call t talk t a registered nurse 1-855-7Nplate (1-855-767-5283), Mnday Friday, 9:00 AM 9:00 PM ET Indicatin Nplate is a man-made

More information

MBP 40.0 Orencia IV (abatacept)- Updated policy

MBP 40.0 Orencia IV (abatacept)- Updated policy What s New Medical Pharmaceutical Plicy Nvember 2018 Updates MBP 5.0 Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)- Updated plicy Fr Treatment f Rheumatid Arthritis: Must

More information

ACTEMRA (tocilizumab)

ACTEMRA (tocilizumab) RATIONALE FOR INCLUSION IN PA PROGRAM Background Actemra is an agent in the class of drugs known as biologic disease modifiers. It is used to treat adult onset rheumatoid (RA) arthritis, polyarticular

More information

Alimta (pemetrexed) Document Number: IC 0007

Alimta (pemetrexed) Document Number: IC 0007 Alimta (pemetrexed) Document Number: IC 0007 Last Review Date: 05/01/2018 Date of Origin: 07/20/2010 Dates Reviewed: 09/2010, 12/2010, 03/2011, 06/2011,0 9/2011, 12/2011, 03/2012, 06/2012, 09/2012, 12/2012,

More information

Clinical Policy: Vedolizumab (Entyvio) Reference Number: ERX.SPA.163 Effective Date:

Clinical Policy: Vedolizumab (Entyvio) Reference Number: ERX.SPA.163 Effective Date: Clinical Plicy: Vedlizumab (Entyvi) Reference Number: ERX.SPA.163 Effective Date: 10.01.16 Last Review Date: 11.18 Revisin Lg See Imprtant Reminder at the end f this plicy fr imprtant regulatry and legal

More information

Actemra (tocilizumab) CG-DRUG-81

Actemra (tocilizumab) CG-DRUG-81 Market DC Actemra (tocilizumab) CG-DRUG-81 Override(s) Prior Authorization Approval Duration 1 year Medications Line of Business Quantity Limit Actemra (tocilizumab) vials VA MCD and All L-AGP May be subject

More information

US Public Health Service Clinical Practice Guidelines for PrEP

US Public Health Service Clinical Practice Guidelines for PrEP Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S

More information

Chimeric Antigen Receptor T cell Therapy (CAR-T)

Chimeric Antigen Receptor T cell Therapy (CAR-T) Applies t all prducts administered r underwritten by Blue Crss and Blue Shield f Luisiana and its subsidiary, HMO Luisiana, Inc.(cllectively referred t as the Cmpany ), unless therwise prvided in the applicable

More information

Related Policies None

Related Policies None Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER

More information

Rituximab PROTOCOL FOR PAEDIATRIC RHEUMATOLOGY

Rituximab PROTOCOL FOR PAEDIATRIC RHEUMATOLOGY Rituximab PROTOCOL FOR PAEDIATRIC RHEUMATOLOGY 1. Backgrund and indicatins Rituximab is a mnclnal antibdy that wrks by remving B-cells (a type f white bld cell that prduce antibdies). The aim f the B cell

More information

This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.

This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. This Cverage Plicy applies t Individual Health Insurance Marketplace benefit plans nly. Immunlgical Agents Bilgical Respnse Mdifier-Tumr Necrsis Factr (TNF) Inhibitrs: Enbrel (etanercept fr subcutaneus

More information

High Performance Network Quality Criteria for Designation

High Performance Network Quality Criteria for Designation Selected quality measures include: Specialty Measure Descriptin Allergy / Immunlgy Asthma Drug Mgt Vaccine Pneumnia Vaccine High Perfrmance Netwrk Quality Criteria fr Designatin AvMed has selected certain

More information

Wound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018

Wound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018 Wund Care Equipment and Supply Benefits t Change fr Texas Medicaid July 1, 2018 Infrmatin psted May 11, 2018 Nte: Texas Medicaid managed care rganizatins (MCOs) must prvide all medically necessary, Medicaid-cvered

More information

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health

More information

ITP typically presents with the sudden appearance of a petechial rash, spontaneous bruising and/or bleeding in an otherwise well child.

ITP typically presents with the sudden appearance of a petechial rash, spontaneous bruising and/or bleeding in an otherwise well child. Acute Immune Thrmbcytpenia Purpura (ITP) Backgrund Primary immune thrmbcytpenia (ITP) is an acquired immune mediated disrder characterised by islated thrmbcytpenia, defined as a peripheral bld platelet

More information

Cimzia (certolizumab pegol) (Subcutaneous)

Cimzia (certolizumab pegol) (Subcutaneous) Cimzia (certolizumab pegol) (Subcutaneous) Last Review Date: 06/01/2018 Date of Origin: 11/28/2011 Document Number: IC-0028 Dates Reviewed: 12/2011, 11/2012, 11/2013, 12/2013, 08/2014, 03/2015, 06/2015,

More information

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Retaking NPTE

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Retaking NPTE The table below lists the requirements for retaking the National Physical Therapy Exam (NPTE) for each jurisdiction. Summary Number of attempts on NPTE limited? 16 27 Number of attempts allowed before

More information

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) (NQF 0081) EMeasure Name Heart Failure (HF): Angitensin

More information

ACTEMRA (tocilizumab)

ACTEMRA (tocilizumab) Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced

More information

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) (NQF 0081) EMeasure Name Heart Failure (HF): EMeasure

More information

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Direct Access

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Direct Access Each licensing authority indicates the level of direct access allowed in the jurisdiction and the type of limitations that apply to this access. There are two tables: Types and Limits Referrals TYPES AND

More information

SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745

SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745 Generic Brand HICL GCN Exceptin/Other NALTREXONE CONTRAVE ER 41389 /BUPROPION LORCASERIN BELVIQ 34733 PHENTERMINE PHENTERMINE 20691 20692 20693 20713 PHENTERMINE LOMAIRA 20715 PHENTERMINE/TO PIRAMATE GUIDELINES

More information

CRITERIA FOR USE: Requires Prior Authorization by Medical Director or Designee

CRITERIA FOR USE: Requires Prior Authorization by Medical Director or Designee What s New Medical Pharmaceutical Plicy September Updates 2017 MBP 154.0 Radicava (edaravne)- New Plicy CRITERIA FOR USE: Requires Prir Authrizatin by Medical Directr r Designee Radicava (edaravne) will

More information

Annex III. Amendments to relevant sections of the Product Information

Annex III. Amendments to relevant sections of the Product Information Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t

More information

CDC Influenza Technical Key Points February 15, 2018

CDC Influenza Technical Key Points February 15, 2018 CDC Influenza Technical Key Pints In this dcument: Summary Key Pints U.S. Vaccine Effectiveness U.S. Flu Activity Update Summary Key Pints On Thursday, tw influenza-related reprts appeared in the Mrbidity

More information

Vaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE

Vaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE Vaccine Infrmatin Statement: PNEUMOCOCCAL CONJUGATE VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están

More information

Erythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) (Subcutaneous/Intravenous) *NON DIALYSIS* Document Number: IC 0242

Erythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) (Subcutaneous/Intravenous) *NON DIALYSIS* Document Number: IC 0242 Erythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) (Subcutaneous/Intravenous) *NON DIALYSIS* Document Number: IC 0242 Last Review Date: 05/01/2018 Date of Origin: 10/17/2008 Dates Reviewed:

More information

WARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES

WARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES INDICATION FARYDAK (panbinstat) capsules, a histne deacetylase inhibitr, in cmbinatin with brtezmib and dexamethasne, is indicated fr the treatment f patients with multiple myelma wh have received at least

More information

Subject: Baricitinib (Olumiant ) Tablet

Subject: Baricitinib (Olumiant ) Tablet 09-J3000-10 Original Effective Date: 09/15/18 Reviewed: 08/08/18 Revised: 00/00/00 Subject: Baricitinib (Olumiant ) Tablet THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION

More information

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Direct Access

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Direct Access Each licensing authority indicates the level of direct access allowed in the jurisdiction and the type of limitations that apply to this access. There are two tables: Types and Limits Referrals TYPES AND

More information

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018) Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Actemra) Reference Number: HIM.PA.SP32 Effective Date: 05/17 Last Review Date: Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder at

More information

MEDICARE COVERAGE SUMMARY: TRANSCRANIAL MAGNETIC STIMULATION

MEDICARE COVERAGE SUMMARY: TRANSCRANIAL MAGNETIC STIMULATION OPTUM MEDICARE COVERAGE SUMMARY: TRANSCRANIAL MAGNETIC STIMULATION MEDICARE COVERAGE SUMMARY: TRANSCRANIAL MAGNETIC STIMULATION Guideline Number: Effective Date: April, 2018 INSTRUCTIONS FOR USE This guideline

More information

Q 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?

Q 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder? updated 2012 Relaxatin training Q 5: Is relaxatin training better (mre effective than/as safe as) than treatment as usual in adults with depressive episde/disrder? Backgrund The number f general health

More information

Clinical Policy: Tocilizumab (Actemra) Reference Number: CP.PHAR.263 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Tocilizumab (Actemra) Reference Number: CP.PHAR.263 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Actemra) Reference Number: CP.PHAR.263 Effective Date: 07.01.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the

More information

NPCR CLINICAL EDIT CHECKS

NPCR CLINICAL EDIT CHECKS NPCR CLINICAL EDIT CHECKS FCDS Annual Meeting July 26, 2013 Sunrise, Flrida Steven Peace, CTR FCDS Data Quality Staff PURPOSE OF CLINICAL EDIT CHECKS The primary purpse f the Clinical Check edits is t

More information

CSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009

CSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009 CSHCN Services Prgram Benefits t Change fr Outpatient Behaviral Health Services Infrmatin psted Nvember 10, 2009 Effective fr dates f service n r after January 1, 2010, benefit criteria fr utpatient behaviral

More information

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQ s) Fr PA Health & Wellness Prviders Questin GENERAL Why is PA Health & Wellness implementing a Medical Specialty Slutins Prgram? Answer

More information

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion Intravenus Vancmycin Use in Adults Intermittent (Pulsed) Infusin Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment

More information

Solid Organ Transplant Benefits to Change for Texas Medicaid

Solid Organ Transplant Benefits to Change for Texas Medicaid Slid Organ Transplant Benefits t Change fr Texas Medicaid Infrmatin psted February 13, 2015 Nte: All new and updated prcedure cdes and their assciated reimbursement rates are prpsed benefits pending a

More information

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic

More information

Widening of funding restrictions for rituximab and eltrombopag

Widening of funding restrictions for rituximab and eltrombopag 20 February 2014 Widening f funding restrictins fr rituximab and eltrmbpag PHARMAC is pleased t annunce the apprval f prpsals t widen the restrictin n rituximab use in DHB hspitals and expand the funding

More information

Patient must be 18 years of age or older (unless otherwise specified); AND

Patient must be 18 years of age or older (unless otherwise specified); AND (Intravenus) Last Review Date: January 1, 2019 Number: MG.MM.PH.89 Medical Guideline Disclaimer C All rights reserved. The treating physician r primary care prvider must submit t EmblemHealth the clinical

More information

P02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017

P02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...

More information

Completing the NPA online Patient Safety Incident Report form: 2016

Completing the NPA online Patient Safety Incident Report form: 2016 Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject

More information

Continuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator

Continuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator Cntinuus Quality Imprvement: Treatment Recrd Reviews Third Thursday Prvider Call (August 20, 2015) Wendy Bwlin, QM Administratr Gals f the Presentatin Review the findings f Treatment Recrd Review results

More information

Original Policy Date 12:2013

Original Policy Date 12:2013 MP 5.01.18 Xlair (Omalizumab) Medical Plicy Sectin Prescriptin Drugs Issu12:2013e 4:2006 Original Plicy Date 12:2013 Last Review Status/Date Lcal plicy/12:2013 Return t Medical Plicy Index Disclaimer Our

More information

Immune Globulins (immunoglobulin) (Intravenous)

Immune Globulins (immunoglobulin) (Intravenous) Immune Glbulins (immunglbulin) (Intravenus) Last Review Date: 09/05/2018 Date f Origin: 07/20/2010 Dcument Number: MODA-0071 Dates Reviewed: 09/2010, 12/2010, 02/2011, 03/2011, 06/2011, 09/2011, 10/2011,

More information

NIA Magellan 1 Spine Care Program Interventional Pain Management Frequently Asked Questions (FAQs) For Medicare Advantage HMO and PPO

NIA Magellan 1 Spine Care Program Interventional Pain Management Frequently Asked Questions (FAQs) For Medicare Advantage HMO and PPO NIA Magellan 1 Spine Care Prgram Interventinal Pain Management Frequently Asked Questins (FAQs) Fr Medicare Advantage HMO and PPO Questin GENERAL Why is Flrida Blue implementing a Spine Management prgram

More information

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment r prphylaxis. Evidence supprting this guidance is detailed belw.

More information